Transforming Metastatic Breast Cancer Management: Harnessing the Power of Antibody-Drug Conjugate Therapies

CEConversations

コンテンツは Creative Educational Concepts によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャストコンテンツは、Creative Educational Concepts またはそのポッドキャストプラットフォームパートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。

3M ago 1:33:21

MP3•エピソードのホーム

Patients with triple-negative breast cancer (TNBC), and those with HR-positive/HER2-negative breast cancer after the development of endocrine resistance, have limited treatment options. Black women are diagnosed more often with TNBC and feel the lack of treatment options more acutely, leading to greater outcomes disparities. Antibody-drug conjugates (ADCs) are novel agents that may improve outcomes for patients. However, clinicians lack the ability to implement them into practice appropriately or may be hesitant to use them altogether. This 90-minute enduring activity is led by a panel of breast cancer experts who will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).
Learn more: https://www.ceconcepts.com/activity/transforming-metastatic-breast-cancer-management-harnessing-the-power-of-antibody-drug-conjugate-therapies-2/
Download the slides: https://www.ceconcepts.com/wp-content/uploads/2024/08/MM-140—ASCO—240606-1.pdf
Download the Transcript: https://www.ceconcepts.com/wp-content/uploads/2024/08/MMV-140-Transcript_FINAL.pdf

32 つのエピソード